EastWest Bioscience Inc.
EASTH.V
TSX
| 04/30/2022 | 01/31/2022 | 10/31/2021 | 07/31/2021 | 04/30/2021 | |
|---|---|---|---|---|---|
| Revenue | -59.73% | -34.41% | -19.02% | -29.52% | -39.95% |
| Total Other Revenue | 28.09% | 13.69% | 14.98% | 62.34% | 102.83% |
| Total Revenue | -29.99% | -17.40% | -7.56% | -9.31% | -21.14% |
| Cost of Revenue | -49.87% | -35.97% | -17.07% | -25.19% | -18.01% |
| Gross Profit | -6.64% | 6.05% | 3.46% | 14.29% | -24.54% |
| SG&A Expenses | 93.28% | 96.58% | 55.13% | 24.36% | -31.13% |
| Depreciation & Amortization | -13.53% | -3.39% | -0.66% | -1.17% | -8.16% |
| Other Operating Expenses | -51.08% | -51.08% | -150.00% | 95.38% | 137.17% |
| Total Operating Expenses | 47.37% | 55.40% | 33.73% | 14.73% | -25.02% |
| Operating Income | -126.73% | -120.54% | -68.21% | -35.14% | 28.62% |
| Income Before Tax | 96.26% | 133.41% | -101.32% | -54.70% | 52.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 96.26% | 133.41% | -101.32% | -54.70% | 52.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 108.18% | 143.28% | -89.74% | -52.52% | 52.63% |
| EBIT | -126.73% | -120.54% | -68.21% | -35.14% | 28.62% |
| EBITDA | -144.85% | -134.88% | -75.54% | -38.78% | 30.59% |
| EPS Basic | 103.80% | 134.69% | -74.12% | -34.34% | 57.98% |
| Normalized Basic EPS | -156.72% | -114.86% | -37.80% | -18.68% | 38.53% |
| EPS Diluted | 103.80% | 134.69% | -74.12% | -34.34% | 57.98% |
| Normalized Diluted EPS | -156.72% | -114.86% | -37.80% | -18.68% | 38.53% |
| Average Basic Shares Outstanding | 7.21% | 8.70% | 10.78% | 13.08% | 12.21% |
| Average Diluted Shares Outstanding | 7.21% | 8.70% | 10.78% | 13.08% | 12.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
